Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

Lifotronic Plans to Raise CNY 632 Million in Shanghai Stock Exchange
Lifotronic Plans to Raise CNY 632 Million in Shanghai Stock Exchange
Lifotronic's "Liquid Chromatography." Photo: Lifotronic
Associated Company
EqualOcean EqualOcean

Pharmaceutical manufacturing company Lifotronic's IPO application was accepted by the Shanghai Stock Exchange. It is reported that Lifotronic intends to issue no more than 43 million shares, and plans to raise CNY 632 million. Lifotronic announced that the funds raised will be mainly used for rehabilitation treatment equipment and smart health care products construction projects.

According to the prospectus data, Lifotronic generated CNY 251 million and CNY 323 million from 2017 to 2018 respectively; net profit attributable to owners of the parent company was CNY 81 million in 2018. Among the revenue, in vitro diagnostic products accounted for the majority of the total revenue.

In recent years, Lifotronic has increased its investment in R&D, and established “Academician Workstation”, “Guangdong Engineering Technology Research Center”, “Shenzhen Engineering Technology Research Center”, “Shenzhen Engineering Laboratory”, “Enterprise Technology Center” and "R&D platform for Shenzhen Key Laboratory of Immunoassay and Liquid Chromatography In Vitro Diagnostics". According to public information, Lifotronic's research and development expenses in the past three years were CNY 39 million, CNY 5 million and CNY 67 million respectively, and the proportion of research and development expenses to operating income was 22.60%, 19.92% and 20.61% respectively. At present, Lifotronic develops 8 core technologies, possesses 67 patent technologies, 52 software copyrights and sells 69 medical devices.

The company's In Vitro Diagnostics R&D investment is part of a strategic plan. In 2024, in vitro diagnostics will be the biggest revenue generator for a med-tech company with around USD 80 billion worldwide sales volume. The annual growth rate will be around 6%, which means a sales revenue increase of around USD 25 billion.

"When I was at Mindray, the strategy was to follow what was called the international “GPS” - where GPS here stands for General Electric, Philips, and Siemens - follow their products and imitate their strategy. On the contrary, when I established Lifotronic, while I wanted to learn from the best practices of international companies like Medtronic and J&J, I was also committed to innovating and creating new products as a company." says the founder, Shine Liu Xiancheng.

Indeed Chinese med-tech companies are slowly catching up with their American and Japanese role-models.

Enterprise Information

EqualOcean is a leading industry tech media and an investment research company.
CATEGORIES: AI, Research
Last Funding Type
Series C
Number of Employees
200
Number of Funding Rounds
6
Total Funding Amount
26.79M

Enterprise Information

EqualOcean
EqualOcean is a leading industry tech media and an investment research company.
CATEGORIES: AI, Research
Last Funding Type
Series C
Number of Employees
200
Number of Funding Rounds
6
Total Funding Amount
26.79M

Reach the Author!

Ask the author questions about the copied text

MOST READ

THE LATEST

Any Question

EqualOcean is a leading industrial tech media and investment research company that focuses on technological and industrial innovation in China.

We aim to assist Chinese entrepreneurial enterprises to break into the global market and provide overseas investors, VCs, and enterprises with a deeper understanding of China's business environment and to seize opportunities in China.

Join over 800,000 of your peers